ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

BRAF

B-Raf proto-oncogene, serine/threonine kinase · also BRAF1, BRAF-1 · Mitogen-activated protein kinase kinase kinases

5 programs in company-led studies act on BRAF, from 5 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
regorafenibruleBayerinhibitorphase 4404 runningABL1, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
tovorafenibruleDay One Biopharmaceuticalsinhibitorphase 383 runningARAF, RAF1ChEMBL
BRAF V600E Inhibitor HLX208Fosun Pharma–phase 2127 running–the company's pipeline
belvarafenibruleHanmi Pharmaceuticalinhibitorphase 264 runningARAF, RAF1ChEMBL
claturafenibPfizerinhibitorphase 121 running–the company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.